- Home
- SPNS vs BEAM Comparison
SPNS vs BEAM Comparison
Compare SPNS & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPNS
- BEAM
- Stock Information
- Founded
- SPNS 1982
- BEAM 2017
- Country
- SPNS Israel
- BEAM United States
- Employees
- SPNS N/A
- BEAM N/A
- Industry
- SPNS Computer Software: Prepackaged Software
- BEAM Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SPNS Technology
- BEAM Health Care
- Exchange
- SPNS Nasdaq
- BEAM Nasdaq
- Market Cap
- SPNS 1.6B
- BEAM 1.8B
- IPO Year
- SPNS 1992
- BEAM 2020
- Fundamental
- Price
- SPNS $25.99
- BEAM $17.00
- Analyst Decision
- SPNS Buy
- BEAM Strong Buy
- Analyst Count
- SPNS 4
- BEAM 11
- Target Price
- SPNS $33.50
- BEAM $50.50
- AVG Volume (30 Days)
- SPNS 156.2K
- BEAM 3.0M
- Earning Date
- SPNS 05-08-2025
- BEAM 05-06-2025
- Dividend Yield
- SPNS 3.64%
- BEAM N/A
- EPS Growth
- SPNS 15.18
- BEAM N/A
- EPS
- SPNS 1.29
- BEAM N/A
- Revenue
- SPNS $542,379,000.00
- BEAM $63,518,000.00
- Revenue This Year
- SPNS $4.49
- BEAM N/A
- Revenue Next Year
- SPNS $5.15
- BEAM $6.32
- P/E Ratio
- SPNS $20.15
- BEAM N/A
- Revenue Growth
- SPNS 5.40
- BEAM N/A
- 52 Week Low
- SPNS $23.69
- BEAM $13.53
- 52 Week High
- SPNS $41.22
- BEAM $35.25
- Technical
- Relative Strength Index (RSI)
- SPNS 45.52
- BEAM 40.71
- Support Level
- SPNS $25.17
- BEAM $16.04
- Resistance Level
- SPNS $26.39
- BEAM $17.94
- Average True Range (ATR)
- SPNS 0.84
- BEAM 1.84
- MACD
- SPNS 0.00
- BEAM 0.26
- Stochastic Oscillator
- SPNS 55.56
- BEAM 44.24
About SPNS Sapiens International Corporation N.V. (Cayman Islands)
Sapiens International Corp NV is a provider of software solutions for the insurance industry, with an emerging focus on the financial services sector. The company offers software, solutions, and professional services for property & casualty (P&C); reinsurance; life, pension & annuity (L&A); workers' compensation (WC); medical professional liability (MPL); financial & compliance (F&C); and decision modeling for both insurance and financial markets. The group also provides services for project delivery and implementation services, for its Software Solutions portfolio. Geographically, it operates in the region of North America, Rest of the World, and Europe. It generates revenue from Europe.
About BEAM Beam Therapeutics Inc.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.